3-acetamido-1,2,3,4-tetrahydroquinoline | 945-80-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-acetamido-1,2,3,4-tetrahydroquinoline
• 英文别名: N-(1,2,3,4-tetrahydro-quinolin-3-yl)-acetamide；3(R,S)-methylcarbonylamino-1,2,3,4-tetrahydroquinoline；3-Acetylamino-1,2,3,4-tetrahydrochinolin；N-(1,2,3,4-Tetrahydroquinolin-3-YL)acetamide
• CAS: 945-80-2
• 化学式: C₁₁H₁₄N₂O
• mdl: MFCD09810049
• 分子量: 190.245
• InChiKey: HCEIEGOMGWEGOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-acetamido-1,2,3,4-tetrahydroquinoline 在 盐酸 、 甲醇 、 sodium tungstate 、 双氧水 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 生成 3-amino-1-methoxyquinolin-2-one
  参考文献：
  名称：

  Wasalexins A和B，来自芥末的新植物抗毒素：分离，合成和抗真菌活性。

  摘要：

  芥蓝（Wasabia japonica，同种Eutrema wasabi）中两种植物抗毒素的化学结构测定，芥蓝对黑腿真菌[Leptosphaeria maculans（Desm。）Ces。等人，无性阶段Phoma lingam（Tode ex Fr.）Desm。]，以及它们的合成和对P. lingam和山葵假单胞菌的分离物的抗真菌活性已有报道。

  DOI：

  10.1016/s0960-894x(99)00523-5
• 作为产物：
  描述：

  N-(quinolin-3-yl)-acetamide 在 sodium cyanoborohydride 、 溶剂黄146 作用下， 以91%的产率得到3-acetamido-1,2,3,4-tetrahydroquinoline
  参考文献：
  名称：

  Wasalexins A和B，来自芥末的新植物抗毒素：分离，合成和抗真菌活性。

  摘要：

  芥蓝（Wasabia japonica，同种Eutrema wasabi）中两种植物抗毒素的化学结构测定，芥蓝对黑腿真菌[Leptosphaeria maculans（Desm。）Ces。等人，无性阶段Phoma lingam（Tode ex Fr.）Desm。]，以及它们的合成和对P. lingam和山葵假单胞菌的分离物的抗真菌活性已有报道。

  DOI：

  10.1016/s0960-894x(99)00523-5

文献信息

• 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amide
  申请人：Novartis Corporation

  公开号：US05719141A1

  公开（公告）日：1998-02-17

  Compounds of the formula I ##STR1## in which R.sub.1 is arylamino, N-aryl-N-(lower alkoxy-lower alkyl)-amino, N-aryl-N-aryl-lower alkyl-amino or heterocyclyl bonded via a ring carbon atom, X is a carbonyl or methylene group, R.sub.2 and R.sub.3 independently of one another are hydrogen or lower alkyl or, together with the carbon atom with which they are bonded, are a cycloalkylidene radical, R.sub.4 is hydrogen, lower alkyl, lower alkanoyl or lower alkoxycarbonyl, R.sub.5 is hydroxyl, lower alkanoyloxy or lower alkoxycarbonyloxy, R.sub.6 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkyl-lower alkyl, aryl-lower alkyl or heteroaryl-lower alkyl having 5 to 7 ring atoms in the heteroaryl ring and R.sub.7 is hydrogen or lower alkyl, or R.sub.6 and R.sub.7, together with the carbon atom with which they are bonded, are a cydoalkylidene radical and R.sub.8 denotes an aliphatic, cycloaliphatic-aliphatic or heteroarylaliphatic radical, and their salts can be used as active ingredients for medicaments for treatment of high blood pressure.

  公式I的化合物##STR1##中，其中R.sub.1是芳基氨基，N-芳基-N-(较低烷氧基-较低烷基)-氨基，N-芳基-N-芳基-较低烷基-氨基或通过环碳原子连接的杂环基，X是羰基或亚甲基基团，R.sub.2和R.sub.3彼此独立地是氢或较低烷基，或者与它们连接的碳原子一起是环烷基亚甲基基团，R.sub.4是氢，较低烷基，较低烷酰基或较低烷氧羰基，R.sub.5是羟基，较低烷酰氧基或较低烷氧羰氧基，R.sub.6是氢，较低烷基，较低烯基，较低炔基，环烷基，环烷基-较低烷基，芳基-较低烷基或杂环芳基-较低烷基，在杂环芳基环中有5到7个环原子，R.sub.7是氢或较低烷基，或者R.sub.6和R.sub.7与它们连接的碳原子一起是环烷基亚甲基基团，R.sub.8表示脂肪，环脂肪-脂肪或杂环脂肪基团，它们的盐可用作治疗高血压药物的活性成分。
• Non-peptide gnrh antagonists
  申请人：Roe Bryan Michael

  公开号：US20050222139A1

  公开（公告）日：2005-10-06

  Compounds according to general formula 1, wherein A 1 -A 3 are selected from A 5 and A 6 where A 5 is either ═CR 13 — or ═N— and A 6 is —NR 14 —, —O— or —S—; A 4 is either a covalent bond or A 5 , provided that when A 4 is a covalent bond one of A 1 -A 3 must be A 6 and the other two must be A 5 and when A 4 is A 5 then all of A 1 -A 3 must be A 5 ; R 1 is selected from H, NHY′ and COY 2 , in which case R 2 is H, or R 1 and R2 may both be methyl or together represent ═O; R 3 , R 4 and R 5 are each independently selected from H and lower alkyl groups; R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 are each independently selected from H, lower alkyl groups, NH 2 , halogens (F, CI and Br) O-alkyl, CH 2 NM 2 and CF 3 ; R 13 is selected from H, F, CI Br, NO 2 , NH 2 , OH, Me, Et, OMe, NMe 2 and CF 3 ; R 14 is selected from H, methyl and ethyl; W is selected from ═CH— and ═N—; X is selected from CH 2 , O, S, SO 2 , NH and N lower alkyl; Y 1 is selected from CO-lower alkyl, CO(CH 2 ) b Y 3 , CO(CH 2 ) b COY 3 and CO(CH)NHCOY 3 , where b is 1-3; Y2 is selected from OR 15 , NR 16 R 17 and NH(CH 2 ) C COY 3 , where c is 1-3; Y 3 is selected from OR 15 and NR 16 R 17 ; R 15 is selected from H, lower alkyl and (CH 2 ) a R 16 , where a is 0-4; R 16 and R 17 are each independently selected from H, lower alkyl and (CH 2 ) a R 16 or together are —(CH 2 ) 2 -Z-(CH 2)2 —; R 18 is OH a phenyl group or an aromatic heterocycle selected from pyridyl, pyrimidinyl, pyrazinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl and thiadiazolyl, each of which may optionally have a lower alkyl group substituent; and Z is selected from O, CH 2 , S, SO 2 , NH and N-lower alkyl, are new. They are useful in the treatment of breast and prostate cancer, endometriosis and benign prostate hyperplasia, in the regulation of fertility, and in in vitro fertilisation.

  化合物按照通式1进行选择，其中A1-A3选择自A5和A6，其中A5为═CR13—或═N—，A6为—NR14—，—O—或—S—；A4为共价键或A5，若A4为共价键，则A1-A3中必须有一个为A6，其余两个必须为A5，若A4为A5，则A1-A3全部必须为A5；R1选择自H、NHY′和COY2，此时R2为H，或者R1和R2都可以为甲基，或者一起代表═O；R3、R4和R5各自独立选择自H和较低的烷基基团；R6、R7、R8、R9、R10、R11和R12各自独立选择自H、较低的烷基基团、NH2、卤素（F、CI和Br）、O-烷基、CH2NM2和CF3；R13选择自H、F、CI、Br、NO2、NH2、OH、Me、Et、OMe、NMe2和CF3；R14选择自H、甲基和乙基；W选择自═CH—和═N—；X选择自CH2、O、S、SO2、NH和较低的烷基；Y1选择自CO-较低的烷基、CO(CH2)bY3、CO(CH2)bCOY3和CO(CH)NHCOY3，其中b为1-3；Y2选择自OR15、NR16R17和NH(CH2)CCOY3，其中c为1-3；Y3选择自OR15和NR16R17；R15选择自H、较低的烷基和(CH2)aR16，其中a为0-4；R16和R17各自独立选择自H、较低的烷基和(CH2)aR16，或者一起为—(CH2)2-Z-(CH2)2—；R18为OH、苯基或选择自吡啶基、嘧啶基、吡嗪基、呋喃基、噻吩基、吡咯基、咪唑基、吡唑基、噁唑基、异噁唑基、噻唑基、异噻唑基、三唑基、噁二唑基和噻二唑基的芳香杂环，每个都可以选择具有较低的烷基基团取代基；Z选择自O、CH2、S、SO2、NH和N-较低的烷基。它们在乳腺和前列腺癌、子宫内膜异位症和良性前列腺增生的治疗、生育调节以及体外受精方面有用。
• Non-peptide GnRH antagonists
  申请人：Roe Michael Bryan

  公开号：US20080255109A1

  公开（公告）日：2008-10-16

  Compounds according to general formula 1, wherein A 1 -A 3 are selected from A 5 and A 6 where A 5 is either ═CR 13 — or ═N— and A 6 is —NR 14 —, —O— or —S—; A 4 is either a covalent bond or A 5 , provided that when A 4 is a covalent bond one of A 1 -A 3 must be A 6 and the other two must be A 5 and when A 4 is A 5 then all of A 1 -A 3 must be A 5 ; R 1 is selected from H, NHY′ and COY 2 , in which case R 2 is H, or R 1 and R 2 may both be methyl or together represent ═O; R 3 , R 4 and R 5 are each independently selected from H and lower alkyl groups; R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 are each independently selected from H, lower alkyl groups, NH 2 , halogens (F, Cl and Br) O-alkyl, CH 2 NM 2 and CF 3 ; R 13 is selected from H, F, Cl, Br, NO 2 , NH 2 , OH, Me, Et, OMe, NMe 2 and CF 3 ; R 14 is selected from H, methyl and ethyl; W is selected from ═CH— and ═N—; X is selected from CH 2 , O, S, SO 2 , NH and N-lower alkyl; Y 1 is selected from CO-lower alkyl, CO(CH 2 ) b Y 3 , CO(CH 2 ) b COY 3 and CO(CH 2 ) b NHCOY 3 , where b is 1-3; Y 2 is selected from OR 15 , NR 16 R 17 and NH(CH 2 ) c COY3, where c is 1-3; Y 3 is selected from OR 15 and NR 16 R 17 ; R 15 is selected from H, lower alkyl and (CH 2 ) a R 16 , where a is 0-4; R 16 and R 17 are each independently selected from H, lower alkyl and (CH 2 ) a R 16 or together are —(CH 2 ) 2 -Z-(CH 2 ) 2 —; R 18 is OH, a phenyl group or an aromatic heterocycle selected from pyridyl, pyrimidinyl, pyrazinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl and thiadiazolyl, each of which may optionally have a lower alkyl group substituent; and Z is selected from O, CH 2 , S, SO 2 , NH and N-lower alkyl, are new. They are useful in the treatment of breast and prostate cancer, endometriosis and benign prostate hyperplasia, in the regulation of fertility, and in in vitro fertilisation.

  化合物的一般式为1，其中A1-A3从A5和A6中选择，其中A5是═CR13—或═N—，A6是—NR14—，—O—或—S—; A4是共价键或A5，如果A4是共价键，则A1-A3中必须有一个为A6，另外两个必须为A5，如果A4是A5，则A1-A3必须全部为A5; R1从H，NHY'和COY2中选择，此时R2为H，或者R1和R2都可以是甲基或者一起表示为═O; R3，R4和R5各自独立选择自H和较低的烷基基团; R6，R7，R8，R9，R10，R11和R12各自独立选择自H，较低的烷基基团，NH2，卤素（F，Cl和Br），O-烷基，CH2NM2和CF3; R13从H，F，Cl，Br，NO2，NH2，OH，Me，Et，OMe，NMe2和CF3中选择; R14从H，甲基和乙基中选择; W从═CH—和═N—中选择; X从CH2，O，S，SO2，NH和N-较低的烷基中选择; Y1从CO-较低的烷基，CO(CH2)bY3，CO(CH2)bCOY3和CO(CH2)bNHCOY3中选择，其中b为1-3; Y2从OR15，NR16R17和NH(CH2)cCOY3中选择，其中c为1-3; Y3从OR15和NR16R17中选择; R15从H，较低的烷基和(CH2)aR16中选择，其中a为0-4; R16和R17各自独立选择自H，较低的烷基和(CH2)aR16，或者一起为—(CH2)2-Z-(CH2)2—; R18为OH，苯基或从吡啶基，嘧啶基，吡嗪基，呋喃基，噻吩基，吡咯基，咪唑基，吡唑基，噁唑基，异噁唑基，噻唑基，异噻唑基，三唑基，噁二唑基和噻二唑基中选择的芳香杂环，每个芳香杂环可以选择有较低的烷基基团取代物; Z从O，CH2，S，SO2，NH和N-较低的烷基中选择。它们在乳腺癌和前列腺癌，子宫内膜异位症和良性前列腺增生的治疗，调节生育能力以及体外受精方面有用。
• 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
  申请人：CIBA-GEIGY AG

  公开号：EP0702004A2

  公开（公告）日：1996-03-20

  Verbindungen der Formel I worin R₁ Arylamino, N-Aryl-N-(niederalkoxyniederalkyl)-amino, N-Aryl-N-arylniederalkylamino oder über ein Ringstickstoffatom gebundenes Heterocyclyl bedeutet, X für eine Carbonyl- oder Methylengruppe steht, R₂ und R₃ unabhängig voneinander Wasserstoff oder Niederalkyl bedeuten oder zusammen mit dem Kohlenstoffatom, mit dem sie verbunden sind, einen Cycloalkylidenrest darstellen, R₄ Wasserstoff, Niederalkyl, Niederalkanoyl oder Niederalkoxycarbonyl ist, R₅ Hydroxy, Niederalkanoyloxy oder Niederalkoxycarbonyloxy bedeutet, R₆ Wasserstoff, Niederalkyl, Niederalkenyl, Niederalkinyl, Cycloalkyl, Cycloalkylniederalkyl, Arylniederalkyl oder Heteroarylniederalkyl mit 5 bis 7 Ringatomen im Heteroarylring und R₇ Wasserstoff oder Niederalkyl bedeutet oder R₆ und R₇ zusammen mit dem Kohlenstoffatom, mit dem sie verbunden sind, einen Cycloalkylidenrest darstellen und R₈ einen aliphatischen, cycloaliphatisch-aliphatischen oder heteroarylaliphatischen Rest bedeutet,und ihre Salze können als Arzneimittelwirkstoffe für die Behandlung von Bluthochdruck verwendet werden.

  式 I 的化合物 其中 R₁ 是芳基氨基、N-芳基-N-(低级烷氧基-低级烷基)氨基、N-芳基-N-芳基-低级烷基氨基或通过环氮原子键合的杂环基，X 是羰基或亚甲基，R₂ 和 R₃ 相互独立地是氢或低级烷基或与它们连接的碳原子一起代表亚环烷基，R₄ 是氢、低级烷基、低级烷酰基或低级烷氧基羰基，R₂ 和 R₃ 相互独立地是氢或低级烷基或与它们连接的碳原子一起代表亚环烷基R₄ 是氢、低级烷基、低级烷酰基或低级烷氧羰基，R₅ 是羟基、低级烷酰氧基或低级烷氧羰氧基、R₆ 是氢、低级烷基、低级烯基、低级炔基、环烷基、环烷基-低级烷基、芳基-低级烷基或杂芳基-低级烷基，其中杂芳基环上有 5 至 7 个环原子，R₇ 是氢或低级烷基，或者 R₆ 和 R₇ 与它们所连接的碳原子一起代表环烷基、环烷基-低级烷基、芳基-低级烷基或杂芳基-低级烷基、R₈代表脂肪族、环脂脂族或杂芳脂族基，它们的盐可用作治疗高血压的活性药物成分。
• Understanding Flavin-Dependent Halogenase Reactivity via Substrate Activity Profiling
  作者：Mary C. Andorfer、Jonathan E. Grob、Christine E. Hajdin、Julia R. Chael、Piro Siuti、Jeremiah Lilly、Kian L. Tan、Jared C. Lewis

  DOI：10.1021/acscatal.6b02707

  日期：2017.3.3

  The activity of four native FDHs and four engineered FDH variants on 93 low-molecular-weight arenes was used to generate FDH substrate activity profiles. These profiles provided insights into how substrate class, functional group substitution, electronic activation, and binding affect FDH activity and selectivity. The enzymes studied could halogenate a far greater range of substrates than have been previously recognized, but significant differences in their substrate specificity and selectivity were observed. Trends between the electronic activation of each site on a substrate and halogenation conversion at that site were established, and these data, combined with docking simulations, suggest that substrate binding can override electronic activation even on compounds differing appreciably from native substrates. These findings provide a useful framework for understanding and exploiting FDH reactivity for organic synthesis.